Bioethics News

Investigational Personalized Cellular Therapy Tolerated Well by Patients

April 20, 2015

(Eurekalert) – Genetically modified versions of patients’ own immune cells successfully traveled to tumors they were designed to attack in an early-stage trial for mesothelioma and pancreatic and ovarian cancers at the Perelman School of Medicine at the University of Pennsylvania. The data adds to a growing body of research showing the promise of CAR T cell technology.

The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.